Sunshine Biopharma, Inc. (NASDAQ:SBFM) Stock Short Interest Report for September

Sunshine Biopharma, Inc. (NASDAQ:SBFM) was the recipient of a large increase in short interest in September. As of September 30th, there was short interest totaling 131,478 shares, an increase of 461.6% from the September 15th total of 23,410 shares. Based on an average daily trading volume, of 161,724 shares, the short-interest ratio is currently 0.8 days. Approximately 3.1% of the company’s stock are sold short.

Analyst Ratings Changes

Several brokerages recently issued reports on SBFM. Weiss Ratings upgraded shares of Sunshine Biopharma from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday, September 24th. Wall Street Zen raised shares of Sunshine Biopharma to a “hold” rating in a research note on Saturday, August 15th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Sunshine Biopharma presently has an average rating of “Reduce”.

Sunshine Biopharma Price Performance

SBFM opened at $0.34 on Friday. The firm has a market cap of $1.46 million, a PE ratio of -0.03 and a beta of 1.20. The stock has a 50-day moving average price of $1.01 and a 200-day moving average price of $3.89. Sunshine Biopharma has a 1 year low of $0.33 and a 1 year high of $24.30.

Sunshine Biopharma (NASDAQ:SBFM) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($1.15) EPS for the quarter, beating the consensus estimate of ($1.20) by $0.05. The company had revenue of $9.26 million for the quarter, compared to the consensus estimate of $8.70 million. Sunshine Biopharma had a negative net margin of 17.94% and a negative return on equity of 26.36%. As a group, sell-side analysts anticipate that Sunshine Biopharma will post -1.95 EPS for the current year.

About Sunshine Biopharma

Sunshine Biopharma, Inc is a pharmaceutical and biotechnology company focused on developing and commercializing therapies for cancer and other medical conditions. The company’s research pipeline has included Adva-27a, an anticancer compound designed to target tumors that may be resistant to existing treatments, as well as mRNA-based therapeutic candidates.

Through its Canadian operations, including Nora Pharma, Sunshine Biopharma is also involved in the development, marketing and distribution of prescription and over-the-counter pharmaceutical products.